Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation

被引：17

作者：

Daukshus, Nicole ^{[1
]}

Cirincione, Anthony ^{[2
]}

Siver, Molly ^{[3
]}

Mathew, Sherry ^{[1
]}

Kunvarjee, Binni ^{[1
]}

Chan, Amelia ^{[1
]}

Boelens, Jaap Jan ^{[4
]}

Seo, Susan K. ^{[5
]}

Papanicolaou, Genovefa A. ^{[5
]}

Kernan, Nancy A. ^{[4
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Pharm, 1275 York Ave, New York, NY 10021 USA

[2] Maine Med Ctr, Dept Pharm, Portland, ME 04102 USA

[3] Hackensack Univ Med Ctr, Dept Pharm, Hackensack, NJ USA

[4] Mem Sloan Kettering Canc Ctr, Stem Cell Transplantat & Cellular Therapies, MSK Kids, 1275 York Ave, New York, NY 10021 USA

[5] Mem Sloan Kettering Canc Ctr, Infect Dis Serv, New York, NY 10021 USA

来源：

JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY | 2022年 / 11卷 / 07期

关键词：

adolescents; cytomegalovirus; hematopoietic cell transplant; letermovir; PROPHYLAXIS; INFECTION;

D O I：

10.1093/jpids/piac017

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

There are limited data for letermovir as primary cytomegalovirus (CMV) prophylaxis in patients less than 18 years of age. We report 9 adolescent patients who received letermovir following hematopoietic cell transplantation. No patients developed clinically significant CMV while taking letermovir. Letermovir was well tolerated and efficacious in preventing CMV infections.

引用

页码：337 / 340

页数：4

共 12 条

[1] Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the Inborn Errors, Infectious Diseases and Pediatric Diseases Working Parties of EBMT
Bontant, T.
Sedlacke, P.
Balduzzi, A.
Gaspar, B.
Cesaro, S.
Einsele, H.
Peters, C.
Dalle, J-H
[J]. BONE MARROW TRANSPLANTATION, 2014, 49 (02) : 276 - 279
[2] Camacho-Bydume C, 2020, BIOL BLOOD MARROW TR, V26, pS347
[3] Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation
Chen, Kaiwen
Cheng, Matthew P.
Hammond, Sarah P.
Einsele, Hermann
Marty, Francisco M.
[J]. BLOOD ADVANCES, 2018, 2 (16) : 2159 - 2175
[4] Cho SY., 2019, INT J MOL SCI, V20, P1
[5] Databases USFDA, PREVYMIS LET TABL PR
[6] How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation
Einsele, Hermann
Ljungman, Per
Boeckh, Michael
[J]. BLOOD, 2020, 135 (19) : 1619 - 1629
[7] Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients
Ljungman, Per
Hakki, Morgan
Boeckh, Michael
[J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2011, 25 (01) : 151 - +
[8] Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
Marty, F. M.
Ljungman, P.
Chemaly, R. F.
Maertens, J.
Dadwal, S. S.
Duarte, R. F.
Haider, S.
Ullmann, A. J.
Katayama, Y.
Brown, J.
Mullane, K. M.
Boeckh, M.
Blumberg, E. A.
Einsele, H.
Snydman, D. R.
Kanda, Y.
DiNubile, M. J.
Teal, V. L.
Wan, H.
Murata, Y.
Kartsonis, N. A.
Leavitt, R. Y.
Badshah, C.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (25) : 2433 - 2444
[9] Human Cytomegalovirus Latency and Reactivation in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Stern, Lauren
Withers, Barbara
Avdic, Selmir
Gottlieb, David
Abendroth, Allison
Blyth, Emily
Slobedman, Barry
[J]. FRONTIERS IN MICROBIOLOGY, 2019, 10
[10] Letermovir in paediatric HSCT recipients
Strenger, Volker
Sperl, Daniela
Kubesch, Klaus
Donnerer, Josef
Schwinger, Wolfgang
Zach, Klara
Lackner, Herwig
Benesch, Martin
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (09) : 2820 - 2821

← 1 2 →